Banka BioLoo Posts Strong Standalone Q2 FY27 Turnaround; Order Book Reaches ₹83.4 Crore
Banka BioLoo Ltd · Investor Presentation · 12 Nov 2026, 8:49 pm
Banka BioLoo Posts Strong Standalone Q2 FY27 Turnaround; Order Book Reaches ₹83.4 Crore Banka BioLoo delivered a standalone Q2 FY27 total income of ₹1,656 L (+24.5% YoY), with EBITDA of ₹157 L (9.5% margin) and PAT turning around to ₹41.6 L. Consolidated Q2 EBITDA reached ₹238 L (20.1% margin), driven by Megaliter's high-margin annuity model (~55% EBITDA margin). The unexecuted order book stood at ₹83.4 Cr as of 30th Sep'26 (₹58.5 Cr non-rail), with ₹16 Cr of Q2 orders sourced entirely from Category A+ private clients to improve cash-flow turnaround. Consolidated net debt-to-equity closed at 0.82x.
Original exchange filing (PDF)
More announcements from Banka BioLoo Ltd
- Banka BioLoo Limited has informed the Exchange regarding 'ESOP Trading approval for 5000 equity shares'. · 14 Nov 2026
- Unaudited financial results for the quarter and half year ended 30 September 2026. · 13 Nov 2026
- Banka BioLoo Limited has informed the Exchange regarding 'Financial results for the quarter and half year ended 30 September 2026'. · 12 Nov 2026
- Banka BioLoo Limited has submitted to the Exchange, the financial results for the period ended September 30, 2026. · 12 Nov 2026
- Significant movement in price has been observed in Banka BioLoo Limited. The Exchange, in order to ensure that investors have latest relevant information about the company and to inform the market place so that the interest of the investors is safeguarded, had written to the company. Banka BioLoo Limited has submitted their response. · 10 Nov 2026
- Significant movement in price has been observed in Banka BioLoo Limited. The Exchange, in order to ensure that investors have latest relevant information about the company and to inform the market place so that the interest of the investors is safeguarded, has written to the company. The response from the company is awaited. · 10 Nov 2026
- BANKA BIOLOO LIMITED has informed the Exchange about Board Meeting to be held on 12-Nov-2026 to consider and approve the Half Yearly Unaudited Financial results of the Company for the period ended September 2026 and Other business. · 12 Nov 2026
- To consider and approve the financial results and other inter alia business matters for the period ended September 30, 2026 · 12 Nov 2026
